IntraBio Inc.

IntraBio Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for rare and neurodegenerative diseases with significant unmet medical needs. The company's mission is to develop innovative treatments that can profoundly impact the lifestyle and ongoing life of patients. Headquartered in Austin, Texas, IntraBio leverages expertise from its scientific founders at the University of Oxford and University of Munich, focusing on small-molecule drugs that modulate lysosomal function and intracellular calcium signaling.

IntraBio's product pipeline targets a range of severe neurological conditions. Its lead investigational drug, IB1001 (N-Acetyl-L-Leucine), is an orally administered modified amino acid. The company has successfully brought AQNEURSA (levacetylleucine) to market, receiving U.S. FDA approval and European Commission marketing authorization for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). Other therapeutic areas in its focus include GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), Ataxia-Telangiectasia (A-T), Lewy Body Dementia, Fronto-Temporal Dementia, and has preclinical and clinical programs for conditions such as Alzheimer's disease and Parkinson's disease.

Recent notable developments for IntraBio include the U.S. FDA's approval of AQNEURSA for Niemann-Pick Disease Type C in September 2024, following the acceptance of its New Drug Application for IB1001 for NPC in March 2024. The company also announced positive topline results from its pivotal Phase III clinical trial for Ataxia-Telangiectasia. Led by President & CEO Prof. Mallory Factor KCN, IntraBio completed a $15 million Series C funding round in April 2023 and was valued at $1 billion as of March 2024, positioning itself as a significant player in the rare and neurodegenerative disease therapeutic landscape.